Decriminalization of Diverted Buprenorphine in Burlington,Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths

Abstract

Get full access to this article

View all access options for this article.

References

S.E.

Wakeman and

J.D.

Rich , “Barriers to Medications for Addiction Treatment: How Stigma Kills,” Substance Use & Misuse 53, no. 2 (2018): 330-333.

J.R.

Velander

, “Suboxone: Rationale, Science, Misconceptions,” The Ochsner Journal 18, no. 1 (2018): 23-29.

Doernberg ,

Krawczyk ,

Agus , and

Fingerhood , “Demystifying Buprenorphine Misuse: Has Fear of Diversion Gotten in the Way of Addressing the Opioid crisis?” Substance Abuse 40, no. 2 (2019): 148-153.

Id.

Andraka-Christou and

M.J.

Capone , “A Qualitative Study Comparing Physician-Reported Barriers to Treating Addiction Using Buprenorphine and Extended-Release Naltrexone in U.S. Office-Based Practices,” International Journal of Drug Policy 54 (2018): 9-17.

D.R.

Holtgrave

, “Public Health Errors: Costing Lives, Millions at a Time,” Journal of Public Health Management and Practice 16, no. 3 (2010): 211-215.

Velander, supra note 2.

T.J.

Cicero ,

M.S.

Ellis , and

H.D.

Chilcoat ,. “Understanding the Use of Diverted Buprenorphine,” Drug and Alcohol Dependence 193 (2018): 117-123.

Wakeman, supra note 1.

10.

Jickling

, “Opioid Deaths Rise in Vermont but Plummet in Chittenden County,” Seven Days, February 14, 2019.